Pay in 4 interest-free payments of $5.92 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
The Phase 2 trial demonstrated that higher doses produce greater reductions in body weight, with the 12mg group achieving 24.2% average weight loss at 48 weeks
Key Details: Eli Lilly launched its Employer Connect program in March 2026 with more than 15 independent partners, each offering a different model for employers to cover Zepbound
B., Saxena, M., Niaz, M
Type 2 diabetes is a complex condition that requires personalized approaches to treatment, and results from SURPASS-4 demonstrate the potential of tirzepatide to be an important option to help reduce A1C and weight for people with type 2 diabetes on one or up to three oral medicines, said John Doupis, M.D., Ph.D., senior SURPASS-4 Investigator and Director of the Diabetes Division and Clinical Research Center at the Iatriko Paleou Falirou Medical Center in Athens, Greece
Phytopathology 85, 12251230
US$ 24.65
US$ 23.24
US$ 20.63
US$ 24.66
